Please use a minimum of three unique search words
Our search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Emgality ® ▼ (galcanezumab)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
How to confirm an Emgality®▼ (galcanezumab) dose has been injected
The pre-filled pen has visual and audible signals to confirm the injection was successfully completed.
When is the injection complete?
After you press the teal-coloured injection button, you will hear 2 loud clicks.
- Press and hold the injection button; you will hear a loud click
- You will hear a second click in about 5 to 10 seconds after the first one.
- This second click tells you that the injection is complete. 1
You will know the injection is complete when you can see the grey plunger at the top of the clear base. 1
What if more than 2 clicks are heard during the injection - 2 loud clicks and a soft one, is the injection complete?
Some patients may hear a soft click right before the second loud click. That is normal operation of the pen. The pen should not be removed from the skin until the second loud click is heard.1
Patients with vision or hearing problems should not use the pen without help from a caregiver.1
Please find below a short video that demonstrates what audible and visual signals the user will hear and see that will help confirm the dose of galcanezumab has been successfully administered.
References
1Emgality [instructions for use]. Eli Lilly Nederland B.V., The Netherlands.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Date of Last Review: 24 December 2021
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com
Available Mon - Fri, 10am - 4pm, excluding Bank Holidays